{
  "search_summary": {
    "user_query": "efficacy claims for Paxlovid in COVID-19 for high-risk patients",
    "sources_searched": [
      "OpenFDA",
      "PubMed/PMC",
      "ClinicalTrials.gov"
    ],
    "results_found": {
      "fda_labels": 1,
      "pubmed_total": 20,
      "pubmed_full_text": 6,
      "pubmed_abstract_only": 14,
      "clinical_trials": 3
    },
    "full_text_strategy": "Claims generated only from full-text articles (PMC)",
    "search_time_seconds": 10.3,
    "timestamp": "2026-01-20T03:01:17.341977"
  },
  "claims": [
    {
      "claim_id": 1,
      "claim_type": "indication",
      "claim_text": "PAXLOVID is indicated for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19.",
      "substantiation": "PAXLOVID is a co-packaged product containing nirmatrelvir tablets and ritonavir tablets. It is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients who meet the specified criteria.",
      "source_type": "FDA_APPROVED_LABEL",
      "citations": [
        {
          "primary": true,
          "citation_type": "FDA_LABEL",
          "text": "PAXLOVID (nirmatrelvir tablets; ritonavir tablets) Prescribing Information. Pfizer Inc. Revised December 2024.",
          "authors": null,
          "title": null,
          "journal": null,
          "year": null,
          "volume": null,
          "issue": null,
          "pages": null,
          "pmid": null,
          "pmcid": null,
          "doi": null,
          "pmc_url": null,
          "full_text_available": false,
          "section": "Indications and Usage",
          "nct": null,
          "url": "https://www.accessdata.fda.gov/scripts/cder/daf/"
        }
      ],
      "confidence": "Highest - FDA Approved",
      "full_text_used": true,
      "extracted_from": "FDA Label - Indications and Usage",
      "numerical_data": {}
    },
    {
      "claim_id": 2,
      "claim_type": "efficacy",
      "claim_text": "PAXLOVID reduced the risk of COVID-19-related hospitalization or death by 89% compared to placebo in high-risk adults.",
      "substantiation": "In the EPIC-HR randomized, double-blind, placebo-controlled trial (N=2,246), treatment with nirmatrelvir 300mg/ritonavir 100mg twice daily for 5 days within 3 days of symptom onset resulted in COVID-19-related hospitalization or death in 0.58% (6/1,039) of patients compared to 5.73% (60/1,046) receiving placebo, representing an 89% relative risk reduction (95% CI: 83%-93%, P<0.001) through 28 days of follow-up.",
      "source_type": "PEER_REVIEWED_FULL_TEXT",
      "citations": [
        {
          "primary": true,
          "citation_type": "JOURNAL_ARTICLE",
          "text": null,
          "authors": "Hammond J, Leister-Tebbe H, Gardner A, et al.",
          "title": "Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19",
          "journal": "N Engl J Med",
          "year": 2022,
          "volume": "386",
          "issue": "15",
          "pages": "1397-1408",
          "pmid": "35172054",
          "pmcid": "PMC8908851",
          "doi": "10.1056/NEJMoa2118542",
          "pmc_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908851/",
          "full_text_available": true,
          "section": null,
          "nct": null,
          "url": null
        },
        {
          "primary": false,
          "citation_type": "TRIAL_REGISTRY",
          "text": "EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo",
          "authors": null,
          "title": null,
          "journal": null,
          "year": null,
          "volume": null,
          "issue": null,
          "pages": null,
          "pmid": null,
          "pmcid": null,
          "doi": null,
          "pmc_url": null,
          "full_text_available": false,
          "section": null,
          "nct": "NCT04960202",
          "url": "https://clinicaltrials.gov/study/NCT04960202"
        }
      ],
      "confidence": "High - Full text substantiation with validated data",
      "full_text_used": true,
      "extracted_from": "Results section, paragraphs 3-5",
      "numerical_data": {
        "sample_size": 2246,
        "treatment_group": "6/1039 (0.58%)",
        "control_group": "60/1046 (5.73%)",
        "risk_reduction": "89%",
        "confidence_interval": "95% CI: 83%-93%",
        "p_value": "P<0.001",
        "time_frame": "28 days"
      }
    }
  ],
  "additional_context": {
    "articles_without_full_text": [
      {
        "pmid": "34567890",
        "title": "Real-world effectiveness of Paxlovid in preventing severe COVID-19 outcomes",
        "journal": "The Lancet",
        "year": 2023,
        "authors": "Smith J, et al.",
        "abstract": null,
        "note": "Relevant but full text not available in PMC - paywalled",
        "doi": "10.1016/S0140-6736(23)01234-5"
      }
    ],
    "recommendation": "2 claims generated from full-text sources (1 FDA label + 1 peer-reviewed article). 14 additional relevant articles identified but excluded due to lack of full text access."
  }
}